GBIO - Generation Bio Operating profit EBITDA
Current royalties from the sale of non-viral DNA delivery methods provide short-term stability for Generation Bio Co. (GBIO), while long-term success relies on attracting elite geneticists and large-scale R&D. The absolute EBITDA trend visualizes this balance, and 0.00 indicates the current level of the metric. Developments in bypassing the immune response via innovative lipid nanoparticles and ceDNA further strengthen the foundation.
Summary analytical data breakdowns for Generation Bio (GBIO)
- stock quotes and analyst forecast:
- market capitalization statistics:
- book value of equity indicators:
- company total debt and liquidity indicators:
- financial results and valuation multiples details:
GBIO - Company Net Income|Expected Net Profit Generation Bio Co.|GBIO - Price to Earnings Ratio|Future Price to Earnings Multiple Generation Bio Co|GBIO - PEG Multiple|Enterprise Value to EBITDA Ratio Generation Bio|GBIO - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Generation Bio|GBIO - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months generationbio.com|GBIO - Earnings growth in current year|Net earnings per one share growth forecast for next year Generation Bio Co.
Fundamental company valuation:Generation Bio Co.
Generation Bio Co. (GBIO) strategic alliances to develop non-viral DNA delivery systems drive the cash flow dynamics reflected in the net operating income before depreciation. This indicator measures core business efficiency excluding depreciation and taxes, allowing investors to assess the company's actual ability to generate cash and avoid overpaying for the asset amid macroeconomic cooling.
Who Generation Bio Co. competes with
Income before deduction of interest, taxes and amortization TEM|Qiagen N.V. - Operating profit EBITDA|IONS - Operating profit EBITDA|RGEN (Repligen) - Operating profit before deduction of amortization|RNA: Company profit before taxes, interest and amortization|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|GeneDx Corp (WGS) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Ultragenyx Pharmaceutical (RARE)|BEAM - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Sarepta SRPT|TWST: Operating profit before amortization|TXG: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization NTLA (Intellia Corp)|STOK: Operating profit EBITDA|BLFS (biolifesolutions.com) - Profit before payment of interest, taxes and amortization|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Maze Therapeutics, Inc. (MAZE) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Sionna Pharma (SION)|PRME - Profit before interest, taxes and amortization|Taysha Gene Therapies - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization QURE|MeiraGTx - Operating profit EBITDA|REGENXBIO Inc (RGNX) - Operating profit before deduction of amortization|Solid Bio (SLDB) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Ocugen Pharma (OCGN)|Operating profit before deduction of amortization PACB|benitec.com (BNTC) - Operating income before deduction of amortization|Operating profit EBITDA DSGN|Rocket Pharma (RCKT) - Operating profit before depreciation charges|Operating profit EBITDA FDMT (4D Molecular Therapeutics Inc)|Lexeo Therapeutics Inc. - Profit before payment of interest, taxes and amortization|Korro Bio, Inc - Operating profit EBITDA|Operating income before deduction of amortization editasmedicine.com EDIT|Silence Therapeutics plc (SLN) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization ProQR Therapeutics (PRQR)|CDXS (Codexis Inc) - Operating profit EBITDA|Operating profit before amortization SGMO (Sangamo BioSciences)|Profit before payment of interest, taxes and amortization Nautilus Biotechnology (NAUT)|metagenomi.co - Operating profit before amortization|Operating profit EBITDA DTIL (Precision BioSciences, Inc.)|Operating profit EBITDA Boundless Bio Inc. BOLD|Exicure Corp - Operating profit EBITDA|Operating profit before depreciation charges Imunon, Inc. (IMNN)|PHIO: Operating profit EBITDA|Profit before interest, taxes and amortization Mustang Bio (MBIO)|Profit before payment of interest, taxes and amortization TransCode Therapeutics Inc.|Operating profit before amortization BNGO (Bionano)|Operating profit EBITDA APDN|BLUE - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization ImmunoPrecise Antibodies Ltd. IPA|Income before deduction of interest, taxes and amortization OMGA|Singular Genomics - Operating profit EBITDA|RGLS - Operating profit EBITDA|SYRS (Syros) - Operating profit before deduction of amortization|TBIO: Company profit before taxes, interest and amortization|TCON (TRACON Pharmaceuticals) - Operating profit EBITDA|unitybiotechnology.com (UBX) - Operating income before deduction of amortization
